Eloralintide weight loss study for adults with excess weight and type 2 diabetes
Tests eloralintide against placebo for weight loss in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Key facts
- Where
- Guadalajara, Mérida, and Monterrey, MexicoSee the 5 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes and a BMI of 27 kg/m2 or more. It compares eloralintide with placebo for weight loss.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with overweight or obesity (BMI ≥ 27 kg/m2).
- Earlier treatment
- Must be on stable treatment for type 2 diabetes for at least 90 days before screening. Must not have taken amylin analogs, GLP-1 receptor agonists, GIP/GLP receptor agonists or insulin, or weight-loss medicines or remedies, within 90 days before screening.
Main reasons for not taking part
- Type 1 diabetes
- Prior or planned surgery, endoscopic procedure or device-based therapy for obesity (some exceptions apply)
- Heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for heart failure within 90 days before screening
- Class IV congestive heart failure (New York Heart Association)
- Body weight change of 5% or more in the 90 days before screening
Read by machine on 12 November 2026.
Where in Mexico
- Centro de Investigacion Medica de Occidente, S.C.Guadalajara, MexicoContact: Emilia Pelayo Orozco (principal investigator)Not yet recruiting
- Instituto Jalisciense de Investigacion en Diabetes y ObesidadGuadalajara, MexicoContact: Guillermo Gonzalez Galvez (principal investigator)Not yet recruiting
- Unidad de Investigación Clínica y Atención Médica HEPA S.C.Guadalajara, MexicoContact: Marisol Herrera Marmolejo (principal investigator)Not yet recruiting
- Medical Care and Research Sa de CvMérida, MexicoContact: José Cetina Canto (principal investigator)Not yet recruiting
- Cardiolink Clin TrialsMonterrey, MexicoContact: Elias Alberto Garcia Cantu (principal investigator)Not yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07282600EU 2025-523658-15-00
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.Read full original descriptionShow less
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Inclusion: Have type 2 diabetes; Are on stable treatment for type 2 diabetes for at least 90 days prior to screening; Have a BMI ≥ 27 kg/m2; Have a stable body weight (<5% body weight change) for 90 days prior to screening.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure; Have taken any of the following antihyperglycemic medications within 90 days before screening:; amylin analogs; glucagon-like peptide-1 (GLP-1) receptor agonists; glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or; insulin.